NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Inclusion Criteria: 1. Karnofsky Performance Status (KPS) at 70% or more. 2. Non-small cell lung cancer, pancreatic adenocarcinoma, melanoma or lymphoma for which a standard, approved therapy is not available. Patients must have lesions that are evaluable by RECIST criteria. 3. All Adverse Events of any prior chemotherapy, surgery, or radiotherapy, must have resolved to CTCAE (v. 3.0) Grade 1 or less(except for hemoglobin). 4. Adequate bone marrow, renal, liver function. 5. Signed informed consent. Exclusion Criteria: 1. Recent administration of chemotherapy, biological, immunotherapy or investigational agent, major surgery, or radiotherapy. 2. Intrathecal therapy. 3. Known brain metastases. 4. Significant cardiac disease. 5. Prior treatment with vorinostat or NPI-0052, or other HDACi (including valproic acid) or proteasome inhibitors. 6. Known allergy to any component of vorinostat. Prior hypersensitivity reaction of CTCAE Grade \> 3 to therapy containing propylene glycol or ethanol. 7. Pregnant or breast-feeding women. 8. Concurrent, active secondary malignancy for which the patient is receiving therapy. 9. Significant active infection.